AU2010326633A1 - Pharmaceutical compositions for the stimulation of stem cells. - Google Patents
Pharmaceutical compositions for the stimulation of stem cells. Download PDFInfo
- Publication number
- AU2010326633A1 AU2010326633A1 AU2010326633A AU2010326633A AU2010326633A1 AU 2010326633 A1 AU2010326633 A1 AU 2010326633A1 AU 2010326633 A AU2010326633 A AU 2010326633A AU 2010326633 A AU2010326633 A AU 2010326633A AU 2010326633 A1 AU2010326633 A1 AU 2010326633A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- previous
- pharmaceutical
- stem cells
- fgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 51
- 230000000638 stimulation Effects 0.000 title claims abstract description 9
- 239000002269 analeptic agent Substances 0.000 claims abstract description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 96
- 230000000747 cardiac effect Effects 0.000 claims description 25
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 22
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 108010023082 activin A Proteins 0.000 claims description 16
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 15
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 13
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 13
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 13
- 210000005003 heart tissue Anatomy 0.000 claims description 13
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 12
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 12
- 102000019034 Chemokines Human genes 0.000 claims description 12
- 108010012236 Chemokines Proteins 0.000 claims description 12
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- LKBSMPFEKIBRGC-UHFFFAOYSA-N 2-[[2-(4-methoxyanilino)-4-pyrimidinyl]amino]ethanol Chemical compound C1=CC(OC)=CC=C1NC1=NC=CC(NCCO)=N1 LKBSMPFEKIBRGC-UHFFFAOYSA-N 0.000 claims description 11
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 11
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 11
- -1 deirudin Chemical compound 0.000 claims description 11
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- 210000002216 heart Anatomy 0.000 claims description 10
- 229940100601 interleukin-6 Drugs 0.000 claims description 10
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims description 9
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 9
- 108010041776 cardiotrophin 1 Proteins 0.000 claims description 9
- 239000011164 primary particle Substances 0.000 claims description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- 229930002330 retinoic acid Natural products 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229960001727 tretinoin Drugs 0.000 claims description 8
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 208000019622 heart disease Diseases 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 239000011163 secondary particle Substances 0.000 claims description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 4
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 4
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 4
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 4
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920001634 Copolyester Polymers 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 102100020997 Fractalkine Human genes 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 102000004858 Growth differentiation factor-9 Human genes 0.000 claims description 4
- 108090001086 Growth differentiation factor-9 Proteins 0.000 claims description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 4
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 4
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 4
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 4
- 102100026236 Interleukin-8 Human genes 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 108010056852 Myostatin Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 4
- 102000036693 Thrombopoietin Human genes 0.000 claims description 4
- 108010041111 Thrombopoietin Proteins 0.000 claims description 4
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 239000002077 nanosphere Substances 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 2
- BWRRWBIBNBVHQF-UHFFFAOYSA-N 4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2N=CC=CC=2)=N1 BWRRWBIBNBVHQF-UHFFFAOYSA-N 0.000 claims description 2
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 claims description 2
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 claims description 2
- 102000009840 Angiopoietins Human genes 0.000 claims description 2
- 108010009906 Angiopoietins Proteins 0.000 claims description 2
- 102400000345 Angiotensin-2 Human genes 0.000 claims description 2
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 2
- 108010081589 Becaplermin Proteins 0.000 claims description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 2
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 claims description 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 2
- 102100025597 Caspase-4 Human genes 0.000 claims description 2
- 101710090338 Caspase-4 Proteins 0.000 claims description 2
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 108010083698 Chemokine CCL26 Proteins 0.000 claims description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 2
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims description 2
- 108010010786 Cholesterol 25-hydroxylase Proteins 0.000 claims description 2
- 102000016917 Complement C1 Human genes 0.000 claims description 2
- 108010028774 Complement C1 Proteins 0.000 claims description 2
- 108010028780 Complement C3 Proteins 0.000 claims description 2
- 102000016918 Complement C3 Human genes 0.000 claims description 2
- 102000012192 Cystatin C Human genes 0.000 claims description 2
- 108010061642 Cystatin C Proteins 0.000 claims description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 claims description 2
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 claims description 2
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 claims description 2
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 claims description 2
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 claims description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 2
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 2
- 108050005077 Haptoglobin Proteins 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 2
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 2
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 2
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 claims description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 claims description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 claims description 2
- 102000000426 Integrin alpha6 Human genes 0.000 claims description 2
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 claims description 2
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 claims description 2
- 102100030335 Midkine Human genes 0.000 claims description 2
- 108010092801 Midkine Proteins 0.000 claims description 2
- 101000878182 Mus musculus Fibroblast growth factor 15 Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 claims description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 2
- 108700023477 Nucleoside diphosphate kinases Proteins 0.000 claims description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 2
- 102100037765 Periostin Human genes 0.000 claims description 2
- 101710199268 Periostin Proteins 0.000 claims description 2
- 102100035194 Placenta growth factor Human genes 0.000 claims description 2
- 102000011195 Profilin Human genes 0.000 claims description 2
- 108050001408 Profilin Proteins 0.000 claims description 2
- 239000005700 Putrescine Substances 0.000 claims description 2
- 102000015799 Qa-SNARE Proteins Human genes 0.000 claims description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 claims description 2
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 claims description 2
- 102000005881 S100 Calcium Binding Protein A6 Human genes 0.000 claims description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims description 2
- 102100030511 Stanniocalcin-1 Human genes 0.000 claims description 2
- 101710142157 Stanniocalcin-1 Proteins 0.000 claims description 2
- 108010055297 Sterol Esterase Proteins 0.000 claims description 2
- 102000013265 Syntaxin 1 Human genes 0.000 claims description 2
- 108010090618 Syntaxin 1 Proteins 0.000 claims description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- 102400000757 Ubiquitin Human genes 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 2
- 101150109862 WNT-5A gene Proteins 0.000 claims description 2
- 102000043366 Wnt-5a Human genes 0.000 claims description 2
- 108700020483 Wnt-5a Proteins 0.000 claims description 2
- 229950006323 angiotensin ii Drugs 0.000 claims description 2
- 229960003856 argatroban Drugs 0.000 claims description 2
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 108010055460 bivalirudin Proteins 0.000 claims description 2
- 229960001500 bivalirudin Drugs 0.000 claims description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 2
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003850 dabigatran Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000002744 extracellular matrix Anatomy 0.000 claims description 2
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940076264 interleukin-3 Drugs 0.000 claims description 2
- 229940096397 interleukin-8 Drugs 0.000 claims description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 229960004408 lepirudin Drugs 0.000 claims description 2
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 claims description 2
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 2
- 229960002137 melagatran Drugs 0.000 claims description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 239000003868 thrombin inhibitor Substances 0.000 claims description 2
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 2
- 229960001522 ximelagatran Drugs 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 4
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 1
- 102000014702 Haptoglobin Human genes 0.000 claims 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 description 31
- 206010061216 Infarction Diseases 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 210000004165 myocardium Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000008055 phosphate buffer solution Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 210000000107 myocyte Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- 210000004413 cardiac myocyte Anatomy 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 6
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 6
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004088 microvessel Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 102100036537 von Willebrand factor Human genes 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 241000282887 Suidae Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 150000002266 vitamin A derivatives Chemical class 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- QQAHYSZVJLHCNA-UHFFFAOYSA-N 2-[[2-(4-methoxyanilino)pyrimidin-4-yl]amino]ethanol;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1NC1=NC=CC(NCCO)=N1 QQAHYSZVJLHCNA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101100165554 Mus musculus Bmp5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000056021 human CTF1 Human genes 0.000 description 1
- 102000044162 human IGF1 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2009/066251 | 2009-12-02 | ||
| EP2009066251 | 2009-12-02 | ||
| PCT/EP2010/068700 WO2011067317A1 (en) | 2009-12-02 | 2010-12-02 | Pharmaceutical compositions for the stimulation of stem cells. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2010326633A1 true AU2010326633A1 (en) | 2012-05-31 |
Family
ID=42316097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010326633A Abandoned AU2010326633A1 (en) | 2009-12-02 | 2010-12-02 | Pharmaceutical compositions for the stimulation of stem cells. |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JP2013512877A (ru) |
| KR (1) | KR20120099751A (ru) |
| CN (1) | CN102711798A (ru) |
| AU (1) | AU2010326633A1 (ru) |
| BR (1) | BR112012013164A2 (ru) |
| CA (1) | CA2781493A1 (ru) |
| IL (1) | IL219901A0 (ru) |
| MX (1) | MX2012005976A (ru) |
| NZ (1) | NZ599930A (ru) |
| RU (1) | RU2012120834A (ru) |
| TW (1) | TW201141510A (ru) |
| WO (1) | WO2011067317A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016006885A1 (ko) * | 2014-07-07 | 2016-01-14 | 메디포스트(주) | 자극된 줄기세포 배양액의 발모 촉진능 및 이의 용도 |
| CN105079791A (zh) * | 2015-09-18 | 2015-11-25 | 郑榆坤 | 一种刺激体内内源干细胞的组合物及其应用 |
| RU2634576C1 (ru) * | 2016-10-24 | 2017-10-31 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ стимуляции регенерации тканей |
| CN107050428B (zh) * | 2017-03-23 | 2020-05-05 | 温州医科大学 | Fgf20药物及其对脑创伤的治疗应用 |
| CN107648592B (zh) * | 2017-11-13 | 2021-05-14 | 深圳市喆邦生物工程有限公司 | 趋化因子ccl4作为制备治疗骨折药物的应用 |
| RU2686718C1 (ru) * | 2018-03-12 | 2019-04-30 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro |
| KR102106710B1 (ko) | 2018-10-11 | 2020-05-04 | 강원대학교산학협력단 | 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법 |
| CN111195350A (zh) * | 2020-01-15 | 2020-05-26 | 重庆大学 | IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用 |
| WO2021187895A1 (ko) * | 2020-03-17 | 2021-09-23 | 주식회사 히에라바이오 | 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물 |
| CN111621525B (zh) * | 2020-06-18 | 2021-04-23 | 中赛干细胞基因工程有限公司 | Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途 |
| CN116836920B (zh) * | 2023-08-21 | 2024-05-24 | 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 | 一种无血清培养基及其制备间充质干细胞的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2269461B1 (en) * | 2004-07-30 | 2017-03-22 | Mayo Foundation For Medical Education And Research | Treating cardiovascular tissue |
| US8168588B2 (en) * | 2005-01-25 | 2012-05-01 | Five Prime Therapeutics, Inc. | Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions |
| US9765298B2 (en) * | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
| US8481075B2 (en) * | 2007-12-13 | 2013-07-09 | Beijing Shengyiyao Science & Technology Development Co. Ltd. | Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines |
-
2010
- 2010-12-02 TW TW099141986A patent/TW201141510A/zh unknown
- 2010-12-02 AU AU2010326633A patent/AU2010326633A1/en not_active Abandoned
- 2010-12-02 CN CN201080053800XA patent/CN102711798A/zh active Pending
- 2010-12-02 WO PCT/EP2010/068700 patent/WO2011067317A1/en active Application Filing
- 2010-12-02 JP JP2012541498A patent/JP2013512877A/ja not_active Withdrawn
- 2010-12-02 BR BR112012013164A patent/BR112012013164A2/pt not_active IP Right Cessation
- 2010-12-02 MX MX2012005976A patent/MX2012005976A/es unknown
- 2010-12-02 RU RU2012120834/15A patent/RU2012120834A/ru not_active Application Discontinuation
- 2010-12-02 NZ NZ599930A patent/NZ599930A/en not_active IP Right Cessation
- 2010-12-02 CA CA2781493A patent/CA2781493A1/en not_active Abandoned
- 2010-12-02 KR KR1020127017238A patent/KR20120099751A/ko not_active Application Discontinuation
-
2012
- 2012-05-20 IL IL219901A patent/IL219901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL219901A0 (en) | 2012-07-31 |
| WO2011067317A1 (en) | 2011-06-09 |
| TW201141510A (en) | 2011-12-01 |
| MX2012005976A (es) | 2012-06-25 |
| NZ599930A (en) | 2014-04-30 |
| CN102711798A (zh) | 2012-10-03 |
| CA2781493A1 (en) | 2011-06-09 |
| JP2013512877A (ja) | 2013-04-18 |
| KR20120099751A (ko) | 2012-09-11 |
| BR112012013164A2 (pt) | 2016-03-01 |
| RU2012120834A (ru) | 2014-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2506867B1 (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
| AU2010326633A1 (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
| KR101689415B1 (ko) | 심장병 치료를 위한 약제학적 조성물 | |
| Song et al. | Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP | |
| Kawamoto et al. | Nerve growth factor and wound healing | |
| Nakamura et al. | Function follows form―a review of cardiac cell therapy― | |
| Sanganalmath et al. | Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond | |
| EP1545219A2 (en) | Cell therapy for regeneration | |
| Zisa et al. | Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells | |
| Zisa et al. | Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair | |
| Louzada et al. | Granulocyte-colony stimulating factor treatment of chronic myocardial infarction | |
| Cho et al. | Enhancement of angiogenic efficacy of human cord blood cell transplantation | |
| Jeon et al. | Synergistic effect of sustained delivery of basic fibroblast growth factor and bone marrow mononuclear cell transplantation on angiogenesis in mouse ischemic limbs | |
| Pattar et al. | Application of bioengineered materials in the surgical management of heart failure | |
| CZ20023426A3 (cs) | Přípravek mající mobilizační aktivitu | |
| EP2432482B1 (en) | Pharmaceutical composition for the treatment of heart diseases. | |
| Davis | The cell engraftment hypothesis of cardiac repair | |
| Širmenis et al. | Recovery of infarcted myocardium in an in vivo experiment | |
| JP4790195B2 (ja) | 組織再生剤 | |
| Murthy et al. | Cardiac regeneration | |
| Tateno et al. | Application of hematopoietic cells to therapeutic angiogenesis | |
| Zisa et al. | Intramuscular VEGF activates an SDF1-dependent progenitor cell 2 cascade and an SDF1-independent muscle paracrine cascade for 3 cardiac repair 4 | |
| Zelarayán et al. | Emerging Concepts in Myocardial Pharmacoregeneration | |
| Gojo et al. | Cardiac Regenerative Medicine Cellular Therapy and Tissue Engineering | |
| McDaniel et al. | Intramuscular VEGF activates an SDF1-dependent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |